Literature DB >> 2542595

Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1.

R B Tenser1, K A Hay, W A Edris.   

Abstract

The presence of herpes simplex virus (HSV) latency-associated transcript (LAT) was investigated in sensory ganglion neurons of mice after inoculation with thymidine kinase (TK) mutants of HSV. Ganglion serial sections were examined in order to quantitate numbers of LAT-positive neurons. After inoculation with TK-positive HSV, virus was isolated during latency from explants of most ganglia, and LAT was detected by in situ hybridization in 96% of ganglia. After inoculation with HSV TK mutants, virus was isolated from 0% of ganglia, but LAT was detected in 95 to 100% of ganglia. After inoculation of TK mutants of HSV, therefore, although latent infection as indicated by the isolation of virus from ganglion explants was not detected, the presence of LAT was common. These results suggest that the lack of reactivatable virus after inoculation of HSV TK mutants may be related to a role for HSV TK expression in the reactivation process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542595      PMCID: PMC250801     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion.

Authors:  R B Tenser; M E Dunstan
Journal:  Virology       Date:  1979-12       Impact factor: 3.616

2.  Latent herpetic infections following experimental viraemia.

Authors:  M L Cook; J G Stevens
Journal:  J Gen Virol       Date:  1976-04       Impact factor: 3.891

Review 3.  The organization of the herpes simplex virus genomes.

Authors:  B Roizman
Journal:  Annu Rev Genet       Date:  1979       Impact factor: 16.830

4.  Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.

Authors:  D A Leib; D M Coen; C L Bogard; K A Hicks; D R Yager; D M Knipe; K L Tyler; P A Schaffer
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Pathogenesis of latent herpes simplex virus infection of the trigeminal ganglion in guinea pigs: effects of age, passive immunization, and hydrocortisone.

Authors:  R B Tenser; G D Hsiung
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

6.  Recovery of herpes-simplex virus from human trigeminal ganglions.

Authors:  J R Baringer; P Swoveland
Journal:  N Engl J Med       Date:  1973-03-29       Impact factor: 91.245

7.  Latency of herpes simplex virus in absence of neutralizing antibody: model for reactivation.

Authors:  T Sekizawa; H Openshaw; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1980-11-28       Impact factor: 47.728

8.  Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.

Authors:  G Darby; H J Field; S A Salisbury
Journal:  Nature       Date:  1981-01-01       Impact factor: 49.962

9.  Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants.

Authors:  R J Klein; A E Friedman-Kien; E DeStefano
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

10.  Resistance of peripheral autonomic neurons to in vivo productive infection by herpes simplex virus mutants deficient in thymidine kinase activity.

Authors:  R W Price; A Khan
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

View more
  30 in total

1.  Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences.

Authors:  N M Sawtell; R L Thompson
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 2.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

3.  Virion proteins of Kaposi's sarcoma-associated herpesvirus.

Authors:  Fan Xiu Zhu; Jae Min Chong; Lijun Wu; Yan Yuan
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Restricted expression of herpes simplex virus lytic genes during establishment of latent infection by thymidine kinase-negative mutant viruses.

Authors:  M Kosz-Vnenchak; D M Coen; D M Knipe
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Detection of latent thymidine kinase-deficient herpes simplex virus in trigeminal ganglia of mice using the polymerase chain reaction.

Authors:  A Friedrich; J P Kleim; K E Schneweis
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants.

Authors:  J P Katz; E T Bodin; D M Coen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Specific inhibitors of herpes simplex virus thymidine kinase diminish reactivation of latent virus from explanted murine ganglia.

Authors:  D A Leib; K L Ruffner; C Hildebrand; P A Schaffer; G E Wright; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Latent infections in spinal ganglia with thymidine kinase-deficient herpes simplex virus.

Authors:  T P Leist; R M Sandri-Goldin; J G Stevens
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

9.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

10.  Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression.

Authors:  K R Marshall; R H Lachmann; S Efstathiou; A Rinaldi; C M Preston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.